-The Times of India PATNA: The Bihar government, which keeps crying for more central assistance, could not spend Rs 1472.61 crore in 2012 and surrendered 100 per cent funds in 192 schemes, depriving the beneficiaries of the benefits, according to the CAG report for 2011-12 presented in state assembly on Tuesday. Central funds for several schemes also remained unutilized, it said. The CAG also regretted the lack of objective planning in utilization...

-The Economic Times WASHINGTON: Big Pharma found little support from the small guy on the street as the Indian Supreme Court's decision to reject patent claims of the drug maker Novartis for its celebrated cancer medicine Glivec reverberated across the world. The pharma lobby railed against the decision but the overwhelming sentiment, from physicians to politicians, from academia to media, particularly in a country groaning from the high cost of health care,...

-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...

-Down to Earth   State blames poor financial condition for the move The Bihar government has defended its recent move to lower its minimum wage rate offered to unskilled labourers, saying the state is in poor financial condition. Bihar has lowered its wage rate offered under the Mahatma Gandhi National Rural Employment Guarantee Act (MGNREGA) from Rs 144 to Rs 135, while the state minimum wage is Rs 168. This is despite the...

-The Economic Times To ensure access to healthcare for all, India must harness innovation in discovering drugs, in developing therapeutics and in delivering affordable healthcare. It is in the light of these facts that one should evaluate the impact of the Indian Supreme Court's ruling in the case involving patent protection for Novartis AG's cancer drug, Glivec. Glivec was the first-of-its-kind cancer drug for leukaemia patients with patent protection in nearly 40...